Human medicines European public assessment report (EPAR): Altuvoct, efanesoctocog alfa, Date of authorisation: 17/06/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Altuvoct, efanesoctocog alfa, Date of authorisation: 17/06/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Tolura, telmisartan, Date of authorisation: 04/06/2010, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Tolura, telmisartan, Date of authorisation: 04/06/2010, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Fruzaqla, fruquintinib, Date of authorisation: 20/06/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Fruzaqla, fruquintinib, Date of authorisation: 20/06/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Ritonavir Viatris (previously Ritonavir Mylan), ritonavir, Date of authorisation: 09/11/2017, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Ritonavir Viatris (previously Ritonavir Mylan), ritonavir, Date of authorisation: 09/11/2017, Revision: 21, Status: Authorised

Working arrangement for the collaboration and exchange of information on therapeutic products and medicinal products between DG SANTE/EMA and the New Zealand Ministry of Health

Working arrangement for the collaboration and exchange of information on therapeutic products and medicinal products between DG SANTE/EMA and the New Zealand Ministry of Health

Orphan designation: allogeneic human induced pluripotent stem cell-derived photoreceptor precursor cells Treatment of syndromic inherited retinal dystrophies of the rod-dominant phenotype, 20/05/2026 Positive

Orphan designation: allogeneic human induced pluripotent stem cell-derived photoreceptor precursor cells Treatment of syndromic inherited retinal dystrophies of the rod-dominant phenotype, 20/05/2026 Positive

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness